How imaging is advancing management of dry AMD

Emerging modalities and deep learning are helping to expose an old foe in non-neovascular age-related macular degeneration: reticular pseudodrusen.

Imaging biomarkers and precision medicine

Advances in computational power, and machine learning and diagnostic systems are creating new opportunities for understanding disease mechanisms.

Where genetics, diet and drusen size intersect

A close look at research into how diet may reverse the effect of genetic susceptibility in drusen size progression in age-related macular degeneration.

Will biosimilars find their place in retina?

With patents expiring, an approval pending and legislation aimed at easing regulations, more biosimilars could be coming. But are retina specialists ready?

The complement pathway in geographic atrophy explained

Examining the role of complement factors in advanced disease.

The promise of targeting mitochondria in dry AMD

Mitochondrial therapies have shown the potential to improve visual function in patients with dry age-related macular degeneration.

Understanding role of Ang2 in neovascular AMD

Angiopoietin-2 is an increasingly desirable target in age-related macular degeneration. Here’s why, and an assessment of investigative treatments.

Lessons from CANTREAT: fewer visits, BCVA improvement

Level 1 evidence now supports treat-and-extend vs. monthly intervals for anti-VEGF treatment of neovascular age-related macular degeneration.

Potential of OCT to identify genetic risk in AMD

A look at our work in optical coherence tomography-derived drusen burden in non-advanced age-related macular degeneration.

Has the time come for AMD home monitoring?

An update on the progress of home-based OCT and how it could reduce treatment burden during and beyond the pandemic.

Video Vault

Minimally invasive management of lenticular deposits

Akshay Thomas, MD, MS, of Tennessee Retina demonstrates his surgical technique for removing posterior intraocular lens deposits.